Literature DB >> 25561820

Modified simultaneous integrated boost radiotherapy for an unresectable huge refractory pelvic tumor diagnosed as a rectal adenocarcinoma.

Takuma Nomiya1, Hiroko Akamatsu1, Mayumi Harada1, Ibuki Ota1, Yasuhito Hagiwara1, Mayumi Ichikawa1, Misako Miwa1, Shouhei Kawashiro1, Motohisa Hagiwara1, Masahiro Chin1, Eiji Hashizume1, Kenji Nemoto1.   

Abstract

A clinical trial of radiotherapy with modified simultaneous integrated boost (SIB) technique against huge tumors was conducted. A 58-year-old male patient who had a huge pelvic tumor diagnosed as a rectal adenocarcinoma due to familial adenomatous polyposis was enrolled in this trial. The total dose of 77 Gy (equivalent dose in 2 Gy/fraction) and 64.5 Gy was delivered to the center of the tumor and the surrounding area respectively, and approximately 20% dose escalation was achieved with the modified SIB technique. The tumor with an initial maximum size of 15 cm disappeared 120 d after the start of the radiotherapy. Performance status of the patient improved from 4 to 0. Radiotherapy with modified SIB may be effective for patients with a huge tumor in terms of tumor shrinkage/disappearance, improvement of QOL, and prolongation of survival.

Entities:  

Keywords:  Clinical trial; Image-guided radiotherapy; Neoplasm recurrence; Quality of life; Rectal neoplasms

Mesh:

Year:  2014        PMID: 25561820      PMCID: PMC4277990          DOI: 10.3748/wjg.v20.i48.18480

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

Review 1.  Intraoperative radiotherapy in the multimodality approach to colorectal cancer.

Authors:  Dieter Hahnloser; Michael G Haddock; Heidi Nelson
Journal:  Surg Oncol Clin N Am       Date:  2003-10       Impact factor: 3.495

2.  Simultaneous integrated boost intensity-modulated radiotherapy (SIB‑IMRT) in nasopharyngeal cancer.

Authors:  Evangelia Peponi; Christoph Glanzmann; Guntram Kunz; Christoph Renner; Katja Tomuschat; Gabriela Studer
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

Review 3.  Patterns of local recurrence in rectal cancer after a multidisciplinary approach.

Authors:  Jose M Enríquez-Navascués; Nerea Borda; Aintzane Lizerazu; Carlos Placer; Jose L Elosegui; Juan P Ciria; Adelaida Lacasta; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

4.  A meta-analysis of alcoholic beverage consumption in relation to risk of colorectal cancer.

Authors:  M P Longnecker; M J Orza; M E Adams; J Vioque; T C Chalmers
Journal:  Cancer Causes Control       Date:  1990-07       Impact factor: 2.506

5.  Leisure-time physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group.

Authors:  M E Martínez; E Giovannucci; D Spiegelman; D J Hunter; W C Willett; G A Colditz
Journal:  J Natl Cancer Inst       Date:  1997-07-02       Impact factor: 13.506

Review 6.  Management of stage IV rectal cancer: palliative options.

Authors:  Sean M Ronnekleiv-Kelly; Gregory D Kennedy
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

7.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

8.  Escalated radiation dose alone vs. concurrent chemoradiation for locally advanced and unresectable rectal cancers: results from phase II randomized study.

Authors:  Reena Engineer; K M Mohandas; P J Shukla; S V Shrikhande; U Mahantshetty; S Chopra; M Goel; S Mehta; P Patil; M Ramadwar; K Deodhar; S Arya; Shyam Kishore Shrivastava
Journal:  Int J Colorectal Dis       Date:  2013-01-29       Impact factor: 2.571

Review 9.  Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas.

Authors:  Kwan Ho Cho; Joo-Young Kim; Seung Hoon Lee; Heon Yoo; Sang Hoon Shin; Sung Ho Moon; Tae Hyun Kim; Kyung Hwan Shin; Myonggeun Yoon; Doo-Hyun Lee; Hong Ryull Pyo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-25       Impact factor: 7.038

10.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

View more
  4 in total

1.  Modified simultaneous integrated boost radiotherapy for large retroperitoneal malignant tumor: A case report.

Authors:  Takuma Nomiya; Hiroko Akamatsu; Mayumi Harada; Ibuki Ota; Yasuhito Hagiwara; Mayumi Ichikawa; Misako Miwa; Masaomi Mizutani; Tomoyuki Kato; Akira Nagaoka; Yoshihiko Tomita; Kenji Nemoto
Journal:  Oncol Lett       Date:  2015-04-02       Impact factor: 2.967

2.  Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report.

Authors:  Young-Hsiang Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee; Bing-Jie Shen; Liang-Cheng Chen; Dai-Wei Liu; Wei-Ta Tsai; Po-Hao Lin; Yi-Ting Shih; Feng-Chun Hsu; Shiang-Jiun Tsai; Michael W Y Chan; Hon-Yi Lin
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 3.  Role of modern radiotherapy in managing patients with hepatocellular carcinoma.

Authors:  Liang-Cheng Chen; Hon-Yi Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

4.  Partially ablative radiotherapy (PAR) for large mass tumors using simultaneous integrated boost: A dose-escalation feasibility study.

Authors:  Savino Cilla; Francesco Deodato; Anna Ianiro; Gabriella Macchia; Vincenzo Picardi; Milly Buwenge; Silvia Cammelli; Alice Zamagni; Vincenzo Valentini; Alessio G Morganti
Journal:  J Appl Clin Med Phys       Date:  2018-09-15       Impact factor: 2.102

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.